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Abstract
Background: The Model for End-stage Liver Disease (MELD) has been used as a prognostic tool
since 2002 to predict pre-transplant mortality. Increasing proportions of transplant candidates with
higher MELD scores, combined with improvements in transplant outcomes, mandate the need to study
surgical outcomes in patients with MELD scores of ≥40.
Methods: A retrospective longitudinal analysis of United Network for Organ Sharing (UNOS) data on
all liver transplantations performed between February 2002 and June 2011 (n = 33 398) stratified by
MELD score (<30, 30–39, ≥40) was conducted. The primary outcomes of interest were short- and long-
term graft and patient survival. A Kaplan–Meier product limit method and Cox regression were used. A
subanalysis using a futile population was performed to determine futility predictors.
Results: Of the 33 398 transplant recipients analysed, 74% scored <30, 18% scored 30–39, and 8%
scored ≥40 at transplantation. Recipients with MELD scores of ≥40 were more likely to be younger
(P < 0.001), non-White and to have shorter waitlist times (P < 0.001). Overall patient survival correlated
inversely with increasing MELD score; this trend was consistent for both short-term (30 days and
90 days) and longterm (1, 3 and 5 years) graft and patient survival. In multivariate analysis, increasing
age, African-American ethnicity, donor obesity and diabetes were negative predictors of survival.
Futility predictors included patient age of >60 years, obesity, peri-transplantation intensive care unit
hospitalization with ventilation, and multiple comorbidities.
Conclusions: Liver transplantation in recipients with MELD scores of ≥40 offers acceptable longterm
survival outcomes. Futility predictors indicate the need for prospective follow-up studies to define the
population to gain the highest benefit from this precious resource.
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Introduction
The Model for End-stage Liver Disease (MELD) laboratory
score was adopted in 2002 to quantify the clinical status of
potential liver transplant recipients and to prioritize candidates
for the allocation of donor organs.1 The MELD score is calcu-
lated using three objective values: the international normalized
ratio (INR); serum creatinine, and serum bilirubin. It reflects a
patient’s 3-month mortality risk on a scale of 6–40. Priority for
liver allocation is given to individuals with the highest scores.1,2
The United Network for Organ Sharing (UNOS), a private
non-profit organization, governs the allocation of donor organs
to transplant candidates within the USA. In 2011, median
MELD scores in adults receiving deceased donor livers varied
by region from 19.5 to 36.0. The national median MELD score
was 27.4 When the MELD score was implemented, patients
with scores of >40 were frequently considered to be too ill to
undergo transplantation.5 Since then, transplants among
patients with MELD scores of >40 have increased in frequency
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as patient outcomes have improved.5,6 Between 2006 and 2010,
the proportion of transplant recipients with MELD scores of
≥40 increased from 6.8% to 10.7% across the nation.5 Given
their high waitlist mortality rate and short life expectancy,
these transplant candidates have also demonstrated in small
reports the most significant benefit from liver transplant,
regardless of donor allograft quality. Even in patients with very
high MELD scores, transplantation has been shown to provide
a short-term survival benefit.7
Although the MELD score stratifies patients based on their
risk for mortality without a transplant, it does not necessarily
identify which patients will have the best longterm outcomes
from liver transplantation. This has become increasingly
important in an era of increased metrics and oversight across
health care fields. The present literature addressing liver trans-
plantation in patients with MELD scores of >40 and longer-
term post-transplant outcomes among this group of patients is
scant. The issue has been evaluated only in a single-centre
context8 and no national multicentre studies exist.
This retrospective cohort study uses the UNOS database to
examine post-transplant survival, morbidity and prognostic
indicators of survival in liver allograft recipients with MELD
scores of ≥40 at the time of transplantation. It also explores
futility predictors of early mortality.
Materials and methods
A population-based, longitudinal retrospective review of
patients who became transplant recipients during the period
from 27 February 2002 to 30 June 2011 was conducted using
UNet℠, a secure UNOS online database that comprehensively
shares nationwide information on organ matching.
Inclusion criteria required the patient to have undergone a
transplant performed on or after 27 February 2002 and to have
had a MELD score of 6–60 (n = 56 470). Exclusion criteria
removed patients with approved MELD exception (n =
16 460), a history of one or more liver allograft failures
(n = 4380), and simultaneous kidney, pancreas, intestine, lung
or heart (n = 4688) transplant. The resulting cohort (n =
33 398) was further divided into three groups based on MELD
score at transplant: <30 (n = 24 804); 30–39 (n = 5984), and
≥40 (n = 2610). The primary outcomes of interest were short-
and longterm outcomes in patients with scores of ≥40 com-
pared with those in the other groups. Short-term outcomes
were defined as length of hospitalization, and 30- and 90-day
post-transplantation survival of grafts and patients. Longterm
outcomes were defined as 1-, 3- and 5-year survival. To iden-
tify potential predictors, multiple univariate Cox regression
analyses were completed for clinically suspected risk factors
including: donor and recipient characteristics (including age,
gender and ethnicity); the medical condition of the patient
immediately before transplantation; the cause of the donor’s
death; allograft type, and organ share type. Covariates
including donor and recipient age, gender, body mass index
(BMI), waiting time, total warm ischaemia time, share type
and cause of donor death were used in the multivariate
analysis. Table 1 gives a full list of the variables examined.
For the futility analysis, a nested case–control study was
designed within the cohort of patients with MELD scores of
≥40 (n = 2610). Transplant recipients with MELD scores of
≥40 who died during the study period were included in this
sub-study (n = 660); those with MELD scores of ≥40 who were
lost from follow-up or who remained alive at the end of the
study (censored) were excluded (n = 1950). Futility was
defined as death within 3 months of transplantation. Thus,
patients who died within 3 months were designated as futile
(n = 282). Patients who died after 3 months were considered
as non-futile (n = 378). Multiple logistic regression analyses
were performed to identify potential predictors of futility.
Statistical analysis
Descriptive statistics of clinical and demographic characteristics
were summarized using the chi-squared test or Fisher’s exact
test for categorical variables. Normally distributed continuous
variables such as BMI were tested using one-way analysis of
variance (ANOVA). Non-normally distributed numerical variables
such as hospital length of stay (LoS) were tested using the
Kruskal–Wallis test. Survival curves for three groups were
obtained using the Kaplan–Meier product limit method and
compared using the Cox–Mantel log rank statistic. Patient
death and graft failure represented the endpoints in the
survival analysis. Right censoring was performed for patients
who entered the study at a definite time (e.g. transplantation),
but ceased to remain in follow-up before the endpoints of the
study were observed (e.g. graft failure and death).
For multivariate analysis, predetermined covariates (age,
gender, ethnicity, donor and share type) and variates with a P-
value of ≤0.1 were included in the final model. All probability
values were two-tailed. The type I error rate was set at 0.05.
All statistical analyses were performed using IBM SPSS Statistics
for Mac OS Version 21.0 (IBM Corp., Armonk, NY, USA).
Results
Of the 33 398 transplant recipients analysed, 74%
(n = 24 804) had MELD scores of <30, 18% (n = 5984) had
MELD scores of 30–39, and 8% (n = 2610) had MELD scores
of ≥40 at transplantation. Overall mortality was directly
proportional to MELD score (26%, 28% and 30%, respectively,
in recipients with MELD scores of <30, 30–39 and ≥40).
There were 1735 futile transplants in recipients who died
within 3 months after transplantation. Analysed according to
MELD score subgroup, 4.2% of patients with MELD scores of
<30 (n = 1031), 7.1% of patients with MELD scores of 30–39
(n = 422), and 10.8% of patients with MELD scores of ≥40
(n = 282) underwent futile transplants.
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Table 1 Pretransplant recipient and liver allograft characteristics by Model for End-stage Liver Disease (MELD) score
MELD score category
Recipient characteristics <30
(n = 24 804)
30–39
(n = 5984)
≥40
(n = 2610)
P-value
Age, years, median (IQR) 53 (13) 51 (16) 50 (17) <0.001
Male, n (%) 15 916 (64%) 3567 (60%) 1626 (63%) <0.001
Obese (BMI ≥30 kg/m2), n (%) 7129 (29%) 1519 (25%) 695 (27%) <0.001
Ethnicity, n (%)
White 18 811 (76%) 3916 (65%) 1611 (62%) <0.001
African-American 2214 (9%) 727 (12%) 317 (12%)
Hispanic/Latino 2885 (12%) 1022 (17%) 496 (19%)
Asian 636 (3%) 233 (4%) 141 (5%)
Othera/unknown/mixed 258 (1%) 86 (1%) 45 (2%)
Viral infections, n (%)
HBsAg positive 904 (4%) 329 (6%) 207 (8%) <0.001
HBcAb positive 3858 (16%) 1015 (17%) 501 (19%) <0.001
Hepatitis C positive 8171 (33%) 1795 (30%) 769 (30%)
EBV positive 14 325 (58%) 3096 (52%) 1336 (51%) <0.001
Other comorbidities at transplant, n (%)
Diabetes 4876 (20%) 983 (16%) 376 (14%) <0.001
Portal vein thrombosis 1365 (6%) 283 (5%) 132 (5%) <0.001
PRBC prior to transplantb 317 (1%) 137 (2%) 67 (3%) <0.001
Prior upper abdominal surgery 9299 (38%) 1894 (32%) 733 (28%) <0.001
TIPS 2332 (9%) 431 (7%) 199 (8%) <0.001
Encephalopathy at transplant, n (%)
None 6998 (28%) 851 (14%) 252 (10%) <0.001
Grade I or II 15 000 (61%) 3298 (55%) 1250 (48%)
Grade III or IV 2101 (9%) 1680 (28%) 1044 (40%)
Ascites at transplant, n (%)
Absent 3845 (16%) 732 (12%) 354 (14%) <0.001
Mild 13 673 (55%) 2356 (40%) 904 (35%)
Moderate 6607 (27%) 2740 (46%) 1297 (50%)
Waiting time, days, median (IQR) 82 (250) 14 (85) 8 (37) <0.001
Distance from donor to transplant hospital, miles, median (IQR) 58 (176) 70 (194) 74 (2037) <0.001
MELD score, mean (SD) 18.4 (5.4) 33.9 (2.8) 44.2 (3.7) <0.001
Pre-transplant laboratory results <0.001
Total bilirubin, mg/dl, median (IQR) 3.3 (3.9) 15.9 (21.3) 32.7 (14.3)
Creatinine, mg/dl, median (IQR) 1.0 (0.6) 2.0 (1.5) 2.5 (2.5) <0.001
INR, median (IQR) 1.6 (0.6) 2.4 (1.2) 3.1 (1.8) <0.001
Albumin, g/dl, mean (SD) 2.9 (1.0) 2.6 (1.0) 2.8 (1.0) <0.001
Dialysis in week prior to transplant, n (%) 395 (2%) 1126 (20%) 1221 (47%) <0.001
Dialysis while on waitlist, n (%) 199 (1%) 300 (5%) 273 (11%) <0.001
Hospitalized pre-transplant,c n (%) 2968 (12%) 1144 (19%) 459 (18%) <0.001
Transplant candidate TIPS, n (%) 1865 (8%) 311 (5%) 139 (5%) <0.001
Transplant candidate on life support/ventilator, n (%) 428 (2%) 586 (10%) 393 (15%) <0.001
Medical condition at transplant, n (%)
Hospitalized in ICU 1650 (7%) 2060 (35%) 1424 (55%) <0.001
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Transplant recipient characteristics
The characteristics of transplant recipients are displayed and
compared in Table 1. Gender distributions were similar across
the groups. At transplantation, recipients with MELD scores of
≥40 were slightly younger (median age: 53 years, 51 years and
50 years, respectively, in recipients with MELD scores of <30,
30–39 and ≥40; P < 0.001). Additionally, the group with MELD
scores of ≥40 had a higher proportion of non-White recipients,
including patients of African-American, Hispanic, Asian, Amer-
ican Indian, Alaskan Native, Native Hawaiian and other Pacific
Islander ethnicities (P < 0.001). At transplantation, recipients
with MELD scores of ≥40 had serum chemistry measurement
values higher than those with MELD scores of <30: total biliru-
bin was 10 times higher; creatinine was 2.5 times higher, and
INR was twice as high (P < 0.001). Compared with patients
with MELD scores of <30 or of 30–39, these high MELD score
recipients were also significantly more likely to be dialysed
within 1 week prior to transplantation (2%, 20% and 47%,
respectively, in recipients with MELD scores of <30, 30–39 and
≥40; P < 0.001) and at some other time while on the waiting
list (1%, 5% and 11%, respectively, in recipients with MELD
scores of <30, 30–39 and ≥40; P < 0.001).
A greater proportion of recipients with MELD scores of ≥40
had grade III or IV encephalopathy prior to transplantation.
However, fewer patients had a history of diabetes and portal
vein thrombosis. They were also less likely to have a history of
upper abdominal surgery or a transjugular intrahepatic porto-
caval shunt (TIPS) (P < 0.001). Despite spending significantly
less time on the waiting list (P < 0.001), they were more likely
to have been hospitalized within the 90 days prior to trans-
plantation and to have required mechanical ventilation
(P < 0.001). The most common indication for transplantation
was hepatitis C infection (30%). Recipients with MELD scores
of ≥40 were more likely to receive an organ of regional share
type (P < 0.001). Recipients with MELD scores of <30 were
more likely to receive a split liver (P < 0.001) or a liver from a
local and national share (P < 0.001).
Donor characteristics
Donor characteristics are displayed in Table 2. Patients with
MELD scores of ≥40 were more likely to receive liver allografts
from donors who were younger (median donor age: 41 years,
39 years and 39 years, respectively, in recipients with MELD
scores of <30, 30–39 and ≥40; P < 0.001), non-White
(P < 0.001), and obese (P = 0.001). These donors were less
likely to have a medical history of hypertension and diabetes
(P < 0.001) or to be extended criteria donors (defined as those
aged >60 years or those aged 50–59 years with two of history
of hypertension, serum creatinine >1.4 mg/dl and death result-
ing from stroke). The most common cause of donor death was
stroke, followed by head trauma and anoxia, across all three
MELD score-stratified recipient groups (P = 0.404).
Liver allograft and preservation conditions
The majority of transplanted allografts were whole livers.
Average cold ischaemia time was similar across all groups
Table 1 Continued
MELD score category
Recipient characteristics <30
(n = 24 804)
30–39
(n = 5984)
≥40
(n = 2610)
P-value
On life support 828 (3%) 1090 (18%) 832 (32%)
On ventilator 728 (3%) 954 (16%) 711 (27%)
Hospitalized not ICU 3304 (13%) 2393 (40%) 949 (37%) <0.001
Not hospitalized 19 759 (80%) 1489 (25%) 216 (8%) <0.001
Known malignancy since waitlist 410 (2%) 71 (1%) 31 (1%) <0.001
Share type, n (%)
Local 17 622 (71%) 3940 (66%) 1650 (63%) <0.001
Regional 5149 (21%) 1792 (30%) 860 (33%)
National 2030 (8%) 251 (4%) 98 (4%)
Foreign 3 (0.01%) 1 (0.02%) 2 (0.08%)
Liver graft type, n (%)
Split 2602 (11%) 186 (3%) 84 (3%) <0.001
Whole 22 202 (90%) 5798 (97%) 2526 (97%)
a
Includes American Indian, Alaskan Native, Native Hawaiian, other Pacific Islander.
b
Received ≥5 units of packed red blood cells 48 h prior to transplant as a result of spontaneous portal hypertensive bleeding.
c
Hospitalized within 90 days before transplantation.
BMI, body mass index; EBV, Epstein–Barr virus; ICU, intensive care unit; INR, international normalized ratio; IQR, interquartile range; PRBC,
packed red blood cells; SD, standard deviation; TIPS, transjugular intrahepatic portocaval shunt.
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(8 h; P = 0.082). Total warm ischaemia time, including anasto-
motic time, was significantly longer in the higher MELD score
group (38 min, 39 min and 41 min, in recipients with MELD
scores of <30, 30–39 and ≥40, respectively; P < 0.001).
Split- versus whole-liver allografts
Among recipients with MELD scores of <40, short-term
patient survival was similar for split- and whole-liver allografts
(97%, 95%, and 97%, 94% at 30 days and 90 days, respec-
tively); however, longterm patient survival was better in those
who received split grafts (91%, 86%, 82%, and 89%, 81%,
75%, at 1, 3 and 5 years, respectively; P < 0.001). Among
recipients with MELD scores of ≥40, short-term survival was
better in those who received split grafts (93%, 88% and 92%,
87% at 30 days and 90 days, respectively), whereas longterm
survival was similar (79%, 79%, 69% and 80%, 73%, 69% at
1, 3 and 5 years, respectively).
Univariate regression analysis showed a split graft to confer
no benefit in recipients with MELD scores of ≥40 [hazard ratio
(HR) 0.80, 95% confidence interval (CI) 0.50–1.29; P = 0.357].
However, it showed a reduced risk for mortality in recipients
with MELD scores of <40 (HR 0.70, 95% CI 64–0.78;
P < 0.001). In multivariate analysis adjusted for donor and
recipient age, gender, BMI and waiting time, a split graft
showed no significant effect in terms of patient survival in
recipients with MELD scores of ≥40 (HR 1.56, 95% CI 0.92–
2.66; P = 0.102) and some survival benefit in recipients with
MELD scores of <40 (HR 0.89, 95% CI 0.80–0.99; P = 0.032).
After controlling for confounders, graft survival in split-liver
transplantations did not differ significantly between the groups
[HR 0.72, 95% CI 0.90–1.07 (P = 0.718) in recipients with
MELD scores of <40; HR 1.59, 95% CI 1.00–2.52 (P = 0.049)
in recipients with MELD scores of ≥40]. Overall, the survival
outcomes of split-liver and whole-liver allografts were similar.
Short-term graft and patient survival
Post-transplant hospital LoS was significantly longer in patients
with higher MELD scores (median LoS: 11 days, 14 days and
15 days in recipients with MELD scores of <30, 30–39 and
≥40, respectively; P < 0.001). Incidences of acute rejection
Table 2 Demographic and clinical characteristics of liver allograft donors by recipient Model for End-stage Liver Disease (MELD) score
Characteristics MELD score categories of transplant recipients
<30 30–39 ≥40 P-value
(n = 24 804) (n = 5984) (n = 2610)
Age, years, median (IQR) 41 (30) 39 (29) 39 (29) <0.001
Gender, male, n (%) 14 537 (59%) 3558 (60%) 1570 (60%) 0.189
Race, n (%)
White 17 473 (70%) 3924 (66%) 1659 (64%) <0.001
African-American 3809 (15%) 843 (14%) 365 (14%)
Hispanic/Latino 2771 (11%) 1006 (17%) 478 (18%)
Asian 452 (2%) 129 (2%) 73 (3%)
Othera/unknown/mixed 298 (1%) 82 (2%) 35 (2%)
Obesity (BMI ≥30 kg/m2), n (%) 10 292 (42%) 2592 (43%) 1162 (45%) 0.001
ECD,b n (%) 6028 (27%) 1223 (21%) 540 (21%) <0.001
Hypertension, n (%) 7451 (30%) 1658 (28%) 730 (28%) <0.001
Diabetes mellitus, n (%) 2282 (9%) 487 (8%) 214 (8%) <0.001
HBV core Ab positive, n (%) 1224 (5%) 245 (4%) 101 (4%) <0.001
Controlled donor, n (%) 1075 (4%) 170 (3%) 71 (3%) <0.001
Liver biopsied, n (%) 7793 (31%) 1617 (27%) 657 (25%) <0.001
Cause of death, n (%)
Anoxia 3787 (17%) 1034 (18%) 434 (17%) 0.404
CVA/stroke 9441 (42%) 2363 (40%) 1055 (41%)
Head trauma 8850 (39%) 2365 (40%) 1017 (40%)
CNS tumour 143 (1%) 37 (1%) 16 (1%)
Other 498 (2%) 114 (2%) 49 (2%)
a
Includes American Indian, Alaskan Native, Native Hawaiian, other Pacific Islander.
b
ECD: extended criteria donors according to the kidney allocation system includes donors aged >60 years or aged >50 years with two of the
following: hypertension, serum creatinine >1.5 mg/dl, and death resulting from a stroke.
BMI, body mass index; CNS, central nervous system; CVA, cerebrovascular accident; HBV, hepatitis B virus; IQR, interquartile range.
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episodes between transplantation and discharge were similar
across groups (P = 0.350).
Graft survival at 30 days varied inversely with increasing
MELD score (95%, 93% and 92% in recipients with MELD
scores of <30, 30–39 and ≥40, respectively; P < 0.001). The
same relationship was observed for graft survival at 90 days
(92%, 88% and 87% in recipients with MELD scores of <30,
30–39 and ≥40, respectively; P < 0.001), patient survival at
30 days (97%, 95% and 92% in recipients with MELD scores
of <30, 30–39 and ≥40, respectively; P < 0.001), and patient
survival at 90 days (95%, 91% and 87% in recipients with
MELD scores of <30, 30–39 and ≥40, respectively; P < 0.001).
Figure 1 depicts graft and patient survival curves.
All subgroups had similar rates of graft non-function from
all causes, regardless of increasing MELD score (12%, 11% and
12% in recipients with MELD scores of <30, 30–39 and ≥40,
respectively; P = 0.009). Rates of treatment for rejection within
6 months or within 1 year of transplantation did not vary
directly with increasing MELD score (10% and 10%, respec-
tively, 7% and 11%, respectively, and 10% and 8%, respec-
tively, in recipients with MELD scores of <30, 30–39 and ≥40,
respectively; P < 0.001). The most common cause of graft fail-
ure across the groups was primary graft failure (3%, 3% and
4% in recipients with MELD scores of <30, 30–39 and ≥40,
respectively; P < 0.041). The incidence of recurrent hepatitis
leading to graft failure was higher in the subgroup with MELD
scores of <30 (3%, 2% and 2% in recipients with MELD scores
of <30, 30–39 and ≥40, respectively; P < 0.001). The frequency
of graft failure caused by infection was higher in the group
with MELD scores of ≥40 (1%, 1% and 2% in recipients with
MELD scores of <30, 30–39 and ≥40, respectively; P < 0.001).
There was no difference across the groups in the frequency of
graft failure caused by acute and chronic rejection (1% for all).
Longterm graft and patient survival
Graft survival at 1 year varied inversely with increasing MELD
score (86%, 80% and 77% in recipients with MELD scores of
<30, 30–39 and ≥40, respectively; P < 0.001). Graft survival at
3 years and 5 years showed the same trend (77% and 71%,
72% and 67%, and 69% and 64%, respectively; P < 0.001).
This overall pattern was repeated for patient survival at 1 year
(90%, 84% and 80% in recipients with MELD scores of <30,
30–39 and ≥40, respectively), 3 years (83%, 77% and 73%,
respectively) and 5 years (77%, 72% and 69%, respectively)
(all: P < 0.001) (Fig. 1).
Survival analysis by MELD categories
A separate regression analysis to evaluate the survival hazard of
increasing MELD score was carried out using the entire sample
stratified by MELD score. In univariate Cox regression analysis,
the hazard of graft failure (HRs 1.46, 1.24 and 1.00 in recipients
with MELD scores of <30, 30–39 and ≥40, respectively;
P < 0.001) and patient mortality (HRs 1.66, 1.34 and 1.00,
respectively; P < 0.001) was significantly higher in the subgroup
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Figure 1 (a) Kaplan–Meier curves depicting liver allograft survival by Model for End-stage Liver Disease (MELD) score category (Mantel–
Cox statistic 133.4, P < 0.001). (b) Kaplan–Meier curves for patient survival by MELD score category (Mantel–Cox log rank statistic
199.8, P < 0.001)
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with MELD scores of 40–49. After adjusting for waiting list time,
donor and recipient factors including age, gender and BMI, and
graft characteristics such as a human leukocyte antigen (HLA)
mismatch, share type, and total warm ischaemia time, the sub-
group with MELD scores of 40–49 had a higher risk for mortal-
ity than the group with MELD scores of 30–39 (P = 0.006) and
that with MELD scores of <30 (P = 0.004). Graft survival did
not differ significantly among groups with MELD scores of <30
and 30–39 (P = 0.086), or 50–60 (P = 0.890).
Potential mortality risk predictors
Multiple univariate Cox regression analyses were performed in
groups with MELD scores of ≥40 and <40, respectively, to
determine potential predictors of mortality. As expected, the
risk for mortality was higher in patients receiving livers from
older donors and with MELD scores of ≥40 (P < 0.001).
Donor obesity (P = 0.005) and diabetes (P < 0.001) increased
the risk significantly. Patients with MELD scores of ≥40 who
received livers from African-American donors had a slightly
increased risk for mortality (HR 1.27, P < 0.001), whereas His-
panic ethnicity in the donor decreased the risk (HR 0.92,
P = 0.011). Cause of donor death and type of liver (split or
whole) were not significant predictors (P > 0.05). In both
groups, recipient age of 40–59 years doubled (P < 0.001 and
P < 0.001, respectively) and age of ≥70 years (P < 0.001)
almost quadrupled the patient mortality risk. A requirement
for ICU care between admission for transplantation and hospi-
tal discharge also increased the risk for mortality by 36%
(P = 0.045). Diabetes for a duration of longer than 5 years
(P < 0.001) and 10 years (P = 0.002) in the transplant recipi-
ent increased the mortality risk (HRs 1.69 and 6.28, respec-
tively) compared with that in recipients without diabetes.
Among patients with MELD scores of ≥40, multivariate
analysis adjusting for donor, recipient and graft characteristics
confirmed donor and recipient age, a history of upper abdomi-
nal surgery, and need for life support at transplantation as sig-
nificant negative predictors of graft survival. Recipient and
donor age, history of upper abdominal surgery, and life sup-
port at transplantation were also significant negative predictors
of patient survival (Table 3).
Post-transplant futility analysis
Inclusion criteria for the futility analysis were a MELD score of
≥40 and death during the study period (n = 660). Patients
who were lost from follow-up or who survived for longer than
the study period were excluded (n = 1950). Those who died
within 3 months of transplant were designated as ‘futile’
(n = 282), and the others were designated as ‘non-futile’
(n = 378). Table 4 shows the characteristics of patients in the
futile and non-futile groups.
Futile transplant recipients were more likely to be aged
<40 years (22% versus 15%; P = 0.007) or >60 years (27%
versus 23%; P = 0.007) than their non-futile counterparts.
They were more likely to have received liver allografts of regio-
nal (32% versus 28%; P < 0.001) or national (6% versus 2%;
P = 0.014) share type than a local share type (61% versus
70%; P = 0.014). Recipient gender (P = 0.704), ethnicity
(P = 0.762) and BMI (P = 0.597) were equally distributed
across the futile and non-futile groups. Futile donors were
more likely to be of non-White ethnicity (African-American:
16% versus 14%; Hispanic: 20% versus 18%; Asian: 6% versus
2%; Other: 2% versus 1%; P = 0.043). Futile and non-futile
groups were similar in terms of other donor characteristics
including age, gender, BMI, presence of diabetes or hyperten-
sion, and cause of death.
At the time of listing, futile transplant recipients (n = 282)
were less likely to be hospitalized, but more likely to be
mechanically ventilated if hospitalized (21% versus 12%;
P = 0.002). There was no difference in grade III and IV
encephalopathy, risk for portal vein thrombosis, spontaneous
bacterial peritonitis, marked muscle wasting, history of TIPS,
or previous upper abdominal surgery. Furthermore, futile
patients were more likely to have required ICU admission
(64% versus 52%; P = 0.002) and mechanical ventilation (43%
versus 26%; P < 0.001). However, they were less likely to have
mild to moderate ascites (83% versus 89%; P = 0.002), or suf-
fer from spontaneous bacterial peritonitis (8% versus 10%;
P = 0.023) (Table 4).
In the futile group, 21 patients experienced primary graft
failure. Other causes of graft failure were infection (n = 12),
vascular thrombosis (n = 8), biliary complications (n = 4), and
hepatitis recurrence (n = 4). In the non-futile group, the most
common cause of graft failure was hepatitis recurrence
(n = 42), followed by infection (n = 24), primary graft failure
(n = 30), vascular thrombosis (n = 12), non-hepatitis disease
recurrence (n = 17), acute rejection (n = 9) and biliary com-
plications (n = 7). The average length of post-transplant hospi-
talization was slightly longer in the futile group (26 days
versus 24 days; P < 0.001). Of the futile transplants, 23.8% of
recipients (n = 67) underwent retransplantation after experi-
encing graft failure. As expected, discharge laboratory values
revealed significantly increased levels of aspartate aminotrans-
ferase (AST) (P < 0.001) and alanine aminotransferase (ALT)
(P < 0.001) in the futile group.
In univariate Cox regression analysis, patients with futile
transplants had a significantly higher risk for graft loss (HR
133.06, 95% CI 92.00–192.45; P < 0.001) and mortality (HR
133.87, 95% CI 77.82–166.62; P < 0.001) In a univariate bino-
mial logistic regression analysis, recipients aged <40 years had
a significantly higher risk for futility than those aged 40–
60 years (P = 0.004). Compared with liver allografts from
White donors, receipt of a graft from an Asian donor con-
ferred a 3.12-fold increased futility risk (95% CI 1.30–7.43;
P = 0.011). Liver allografts from the national share were asso-
ciated with significantly increased futility [odds ratio (OR)
3.07, 95% CI 1.35–6.99; P = 0.008]. Recipients requiring ICU
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care prior to transplantation had a more than two-fold greater
risk for futility than those not hospitalized at the time of trans-
plant (OR 2.62, 95% CI 1.35–5.08; P = 0.005). In the same
vein, requirements for mechanical ventilation or inotropic
drugs at transplantation were significantly associated with futil-
ity (OR 2.09, 95% CI 1.46–2.76; P < 0.001). Patients on gan-
cylovir were more likely to have futile transplants (OR 1.76,
95% CI 1.16–2.68; P = 0.008), whereas those on valgancyclovir
were associated with the opposite outcome (OR 0.59, 95% CI
0.39–0.90; P = 0.002). At discharge, increased INR (OR 4.48,
95% CI 2.83–7.09; P < 0.001) significantly increased futility.
Cold ischaemia time, total warm ischaemia time, and waitlist
time did not affect futility. Donor age, gender, diabetes status,
cause of death, and distance from the transplant hospital also
did not predict futility.
Discussion
Over the past decade, the gradual rise in the number of liver
transplant registrants with very high MELD scores has led to
increasing interest in outcomes among this patient population.
Currently, 8% of liver transplants are performed in patients
with MELD scores of ≥40. The few single-centre studies to
have addressed this topic have demonstrated mixed outcomes.
Some report outcomes comparable with those of transplants in
patients with lower MELD scores,3 whereas others note inferior
survival.7–10 This is the first nationwide longitudinal study to
explore survival outcomes and futility predictors in a cohort of
patients with MELD scores of ≥40 who were transplanted dur-
ing the period from 2002 to 2011. The study confirms the cur-
rent literature on graft and patient survival among patients
Table 3 Multivariate Cox regression analyses of graft and patient survival in transplant recipients with Model for End-stage Liver Disease
(MELD) scores of ≥40
Graft survival Patient survival
Factors Levels n AHR (95% CI)a P-value AHR (95% CI)a P-value
Recipient age, years <18 109 Ref
18–39 276 1.78 (0.98–3.24) 0.059 1.95 (0.95–4.03) 0.070
40–59 908 1.93 (1.08–3.45) 0.027 2.41 (1.20–4.86) 0.014
60–69 277 2.63 (1.44–4.82) 0.002 3.72 (1.81–7.63) <0.001
≥70 22 3.31 (1.34–8.20) 0.010 4.65 (1.68–12.93) 0.003
Donor age, years <18 140 Ref Ref
18–39 704 1.61 (1.00–2.58) 0.048 1.53 (0.91–2.60) 0.108
40–59 564 2.08 (1.30–3.35) 0.002 1.86 (1.10–3.13) 0.020
60–69 139 2.57 (1.51–4.40) 0.001 2.28 (1.26–4.12) 0.006
≥70 45 2.59 (1.32–5.08) 0.005 1.64 (0.72–3.74) 0.241
Recipient ethnicity White 963
African-American 201 1.12 (0.84–1.50) 0.426 1.31 (0.95–1.89) 0.099
Hispanic 314 1.21 (0.94–1.57) 0.148 0.79 (0.58–1.07) 0.126
Asian 85 1.47 (0.88–2.48) 0.144 0.39 (0.20–0.76) 0.006
Otherb 29 1.37 (0.60–3.10) 0.453 2.29 (1.23–4.25) 0.009
Previous abdominal surgery No 1056 Ref
Yes 469 1.24 (1.00–1.54) 0.052 1.27 (0.99–1.61) 0.056
Gancyclovir Yes 542 Ref Ref
No 1050 0.79 (0.64–0.98) 0.008 0.72 (0.56–0.92) 0.009
Valgancyclovir Yes 907 Ref Ref
No 685 1.25 (1.00–1.54) 0.044 1.18 (0.93–1.50) 0.176
Life support at transplant No 1042 Ref Ref
Yes 550 1.49 (1.21–1.83) <0.001 1.61 (1.28–2.02) <0.001
Share type Local 988 Ref
Regional 547 0.95 (0.77–1.18) 0.668 0.94 (0.74–1.19) 0.612
National 56 1.42 (0.83–2.44) 0.204 1.28 (0.67–2.44) 0.456
a
AHR: adjusted hazard ratio for donor and recipient age, gender, ethnicity, body mass index, diabetes status, graft type, share type, cold ischae-
mia time, waiting time, valgancyclovir, gancyclovir, previous abdominal surgery, life support at transplantation.
b
Other: American Indian, Alaskan Native, Native Hawaiian, Pacific Islander, unknown and mixed race.
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with high MELD scores. Although findings showed that overall
mortality was statistically higher among patients with MELD
scores of ≥40, the difference was clinically less significant: the
cohort with MELD scores of ≥40 recorded a 30% mortality
rate, whereas the cohort with MELD scores of <30 recorded a
26% mortality rate.
In the present sample, the better than expected survival in the
cohort with MELD scores of ≥40 may be attributed to the
younger age of recipients, and lower prevalences of diabetes,
portal vein thrombosis, hepatitis C virus and Epstein–Barr virus
(EBV) infection. These patients were also less likely to have
required a TIPS procedure for portal hypertensive bleeds, a mar-
ker that is not reflected in the MELD score. They were less likely
to have had previous upper abdominal surgery. The cohort also
had a higher proportion of allografts of regional share type,
indicating the prioritization of these patients over other candi-
dates on the basis of acuity. Despite having fewer preoperative
comorbid conditions, these recipients required more health care
resources, represented by pre-transplant hospitalization, ICU
admission, mechanical ventilation and a longer LoS.
The benefits of transplantation in a patient with a MELD
score of >40 must be weighed against both the greater risks
and increased resource utilization required. Patients with high
MELD scores have been found to have increased incidences of
post-transplant infection, longer ICU and general hospital
stays, and imply increased overall costs.3,8 Several single-insti-
tution reports have demonstrated poorer post-transplant
Table 4 Demographic and clinical characteristics of
transplantations in recipients with Model for End-stage Liver
Disease (MELD) scores of ≥40 by futility status
Characteristics Futile Non-futile P-value
(n = 282) (n = 378
Recipient age, years,
median (IQR)
53 (16) 53 (12) 0.953
Recipient age categories, n (%)
≤17 years 14 (5%) 8 (2%) 0.007
18–39 years 48 (17%) 47 (12%)
40–59 years 145 (51%) 237 (63%)
60–69 years 67 (24%) 83 (22%)
≥70 years 11 (4%) 3 (1%)
Recipient gender male, n
(%)
181 (64%) 248 (66%) 0.704
Donor age, years,
median (IQR)
43 (29) 42 (29) 0.831
Donor gender male, n
(%)
168 (60%) 219 (58%) 0.673
Recipient race, n (%)
White 187 (66%) 246 (65%) 0.762
Hispanic 39 (14%) 64 (17%)
African-American 39 (14%) 45 (12%)
Asian 8 (3%) 13 (3%)
Mixed/unknown/other 9 (3%) 10 (3%)
Recipient BMI, kg/m2,
median (IQR)
27.3 (8.8) 28.2 (7.4) 0.186
Recipient obesity (BMI
≥30 kg/m2), n (%)
89 (32%) 97 (26%) 0.096
Donor BMI, 30 kg/m2,
median (IQR)
26.2 (8.3) 25.8 (6.7) 0.200
Donor obesity (BMI
≥30 kg/m2), n (%)
131 (47%) 186 (49%) 0.484
Dialysis in week prior to
transplant, n (%)
147 (52%) 204 (54%) 0.639
Previous upper
abdominal surgery, n
(%)
91 (32%) 131 (35%) 0.555
Diabetes mellitus, n (%) 52 (18%) 96 (25%) 0.336
Recipient on life support,
n (%)
138 (49%) 122 (32%) <0.001
Medical condition at transplant, n (%)
ICU 181 (64%) 197 (52%) 0.002
Hospitalized but not
ICU
87 (31%) 144 (38%)
Not hospitalized 13 (5%) 37 (10%)
Recipient on gancyclovir 75 (51%) 88 (37%) 0.007
Recipient on
valgancyclovir
59 (40%) 126 (53%) 0.013
Extended criteria donors,
n (%)
74 (27%) 94 (25%) 0.673
Living donors, n (%) 7 (2%) 10 (3%) 0.896
Table 4 Continued
Characteristics Futile Non-futile P-value
(n = 282) (n = 378
Donor race, n (%)
White 159 (56%) 247 (65%) 0.043
Hispanic 57 (20%) 67 (18%)
African-American 16 (6%) 8 (2%)
Asian 16 (6%) 8 (2%)
Mixed/unknown/other 6 (2%) 4 (1%)
Donor diabetes mellitus,
n (%)
34 (12%) 39 (10%) 0.405
Deceased donor cause of death, n (%)
Head trauma 38 (4%) 68 (18%) 0.538
Stroke 138 (49%) 165 (44%)
Anoxia 95 (34%) 132 (35%)
Other/unknown 7 (2%) 10 (3%)
Share type, n (%)
Local 172 (61%) 264 (70%) 0.014
Regional 91 (32%) 105 (28%)
National 18 (6%) 9 (2%)
Regional 1 (0.4%) 0
BMI, body mass index; ICU, intensive care unit; IQR, interquartile
range.
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survival among recipients stratified by increasing MELD
scores.10–13 However, Alexopoulos et al. reported a 1-year sur-
vival rate of 89% among patients with MELD scores of >40,
which was similar to the 1-year survival rate among patients
with MELD scores of <40.5 The 1-year patient survival rate
identified in the present study is, at 80%, inferior to that
reported by Alexopoulos et al.,5 which implies that nationally
patients with MELD scores of >40 do slightly worse overall
than those with lower MELD scores.
Many studies demonstrate increased perioperative compli-
cations and resource utilization in transplant recipients with
higher MELD scores. Axelrod et al.9 found that patients with
MELD scores of 30 utilized 10 times more Medicare spending
than those with MELD scores of 20.10 Given that average
annual spending on an end-stage liver disease patient is
reported to be US$22 424,10 prioritizing of the most critically
ill patients for transplantation is increasingly important. In
the present cohort of recipients with MELD scores of ≥40,
nearly half of all patients received pre-transplant dialysis.
More than half were in the ICU prior to transplantation, and
one-third needed some modality of life support, including
mechanical ventilation and inotropic drugs, during their hos-
pital stay. This finding is consistent with those of other stud-
ies5 and confirms that patients with MELD scores of >40
utilize a disproportionately higher amount of health care
resources. Nonetheless, the rate of retransplantation attributa-
ble to graft failure, the rate of post-transplant infection lead-
ing to graft failure, and postoperative LoS were all lower in
the present study than in that reported by Alexopoulos et al.5
These findings suggest that transplantation in patients with
very high MELD scores may be sound and necessitate further
investigation.
It is important to identify donor and recipient outcome pre-
dictors to determine which of the patients with MELD scores
of ≥40 will survive transplantation. The present regression
analysis revealed that a recipient age of 60–69 years, diabetes
duration of >10 years, African-American ethnicity, donor dia-
betes and obesity were significant negative predictors. Although
Alexopoulos et al. attributed poor outcomes among patients
with MELD scores of ≥40 to the deleterious effects of pro-
longed pre-transplant waiting,5 the present study did not find
waiting time to be a predictor of futility.
Although the difference in overall and 1-, 3- and 5-year
mortality among MELD subgroups was not large, 30-day mor-
tality was found to increase significantly as MELD scores
increased. Patients with MELD scores of ≥40 were more than
twice as likely to die within 30 days of transplant as those with
MELD scores of <30. Thus, the present futility analysis reveals
that there is a subgroup of patients with MELD scores of ≥40
who will not benefit from transplantation, and whose allocated
organs may be better used in patients with more favourable
prognoses. The present study found that recipient age of
>60 years, a BMI of >30 kg/m2, requirements for ICU care or
life support on the waiting list, and liver allograft of national
share, were predictors of futility. Furthermore, high INR, ALT
and AST values at the time of discharge were also positive
predictors of futility. As these were postoperative laboratory
values, they will not help in patient selection, but will be useful
in helping the clinician to monitor such patients more closely.
In Cox regression analysis, after controlling for age, gender,
BMI, HLA mismatch, cold ischaemia time, total warm ischae-
mia time, waiting time, share type, and cause of donor death,
patients with MELD scores of 40–49 were found to have a risk
for mortality that was increased by 95% and 29% over those
with MELD scores of <30 and of 30–39, respectively. After
adjusting for confounders, patients with MELD scores of
40–49 had a graft failure rate that was 60% and 28% higher
than those with MELD scores of <30 and 30–39, respectively.
Furthermore, patients in this futile transplant subgroup were
more likely to experience preoperative acute comorbidities
such as portal vein thrombosis, renal failure requiring dialysis
prior to transplantation, transfusions for a portal hypertensive
bleed, history of TIPS and prior upper abdominal surgery, as
is representative of a sicker population with increased utiliza-
tion of health care resources.
Overall, the present findings suggest that candidates with
MELD scores of ≥40 on the liver transplant waiting list can
derive benefit from the receipt of an allograft. Despite signifi-
cantly higher futility (43%, 32% and 21% in patients with
MELD scores of ≥40, 30–39 and <30, respectively; P < 0.001),
increased overall mortality (25%, 22% and 20% in patients
with MELD scores of ≥40, 30–39 and <30, respectively) and a
probable increase in health care expenses as a result of the pro-
vision of longer post-transplant inpatient care, these patients
meet the expected survival of >50% at 5 years (64% graft sur-
vival and 69% patient survival) and therefore warrant atten-
tion.14 In characterizing the subset of patients with MELD
scores of ≥40 among whom transplantation may be futile, the
present authors conclude that patients aged >60 years, patients
with obesity, those who are hospitalized in the ICU requiring
ventilation, and those with multiple comorbidities are at risk
for futile transplantation. Additionally, postoperative laboratory
studies should be used to identify patients at high risk for
adverse outcomes, and should demand greater clinician atten-
tion. Despite having fewer preoperative comorbid conditions,
the futile group required more health care resources such as
peri-transplant hospitalization, ICU care and life support
measures.
Strengths and limitations
The present study has several strengths. The most significant is
that it is a population-based effectiveness study that used a
robust national database and a follow-up period extending to
almost a decade to elucidate an inadequately studied issue. The
study addressed the timely topic of surgical outcomes in
patients with MELD scores of ≥40 and the causes of futility in
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this particular group, in comparison with groups with lower
MELD scores. The study also adds substantial information on
prognosis after liver transplantation in the most critically ill
patients as defined by UNOS, which may assist clinicians in
making decisions on the allocation of liver allografts. This
information has the potential to influence future guidelines on
managing this particular type of patient. Additionally, because
it is a longitudinal study, the present study is devoid of selec-
tion bias. Two control groups, consisting of patients with
MELD scores of, respectively, <30 and 30–39, were used to
compare survival.
The study has a few limitations. Because of its retrospective
nature, confounding attributable to unobserved variables is
more likely. This limits the present authors’ ability to com-
ment accurately on the more detailed variables such as pri-
mary non-function, post-transplant ICU stay and utilization
of rehabilitation services, or on direct causes of futility. Addi-
tionally, the study design was not that of a randomized
prospective clinical trial. Hence, potential bias may have been
introduced in addition to the instability of the univariate and
multivariate models.
Conclusions
Although the benefits of liver transplantation in patients with
MELD scores of ≥40 must be weighed against the increases in
risk and resource utilization, liver transplantation in recipients
with MELD scores of ≥40 demonstrates a significant increase
in post-transplant survival that is greater than expected. The
subset of patients with higher MELD scores in whom trans-
plant may have inferior survival outcomes includes those aged
>60 years, those with obesity, multiple comorbidities or pre-
transplant ICU hospitalization, and those receiving allografts
from obese or expanded criteria donors. Future prospective
studies are required to further characterize the subset of
patients with MELD scores of ≥40 who are most likely to bene-
fit from transplantation in order to continue to improve the
allocation of this vital resource and to avoid futile transplanta-
tion in the most critically ill patients.
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